Takeda and Portal Instruments develop needle-free drug delivery device

| |
0
109

Takeda Pharmaceutical Company Limited and Portal Instruments (Massachusetts, USA) today announced a collaboration to develop and commercialize Portal’s needle-free drug delivery device for potential use with Takeda’s investigational or approved biologic medicines.

The Portal device was developed at the Massachusetts Institute of Technology (MIT) in the laboratory of Professor Ian Hunter. The technology has the potential for applications across a range of biologic medicines that currently require administration through an injection.

The first Takeda development program to potentially utilize this device will be for investigational use with Entyvio® (vedolizumab), a monoclonal antibody for adults with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD), which is currently administered through intravenous infusion. A Phase III clinical trial program is currently evaluating the efficacy and safety of a subcutaneous formulation of vedolizumab in adults with moderately to severely active UC or CD.

 “There is a need for options to keep improving the experience for patients with life-long, chronic conditions that are managed with the intravenous infusions of biologic medicines,” said Stefan Koenig, Global Program & Brand Lead at Takeda. “This partnership with Portal demonstrates Takeda’s leadership in supporting patients with GI diseases and our commitment to evolve the management of these diseases, such as inflammatory bowel disease, by potentially offering patients the ability to administer treatment in their own at home with a needle-free system.”

Portal’s needle-free drug delivery device delivers the biologic through a pressurized liquid instead of a needle, and has been clinically shown to be less painful and preferred by patients compared to a standard needle-based injection. This needle-free device is expected to be self-administered by patients at home.

SOURCE: takeda
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.
Isaltis Banner